Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) EBITDA Margin (2018)

Historic EBITDA Margin for DiaMedica Therapeutics (DMAC) over the last 1 years, with Q3 2018 value amounting to 277.4%.

  • DiaMedica Therapeutics' EBITDA Margin changed N/A to 277.4% in Q3 2018 from the same period last year, while for Jun 2019 it was 1811.8%, marking a year-over-year change of. This contributed to the annual value of 71844.12% for FY2024, which is 158877000.0% down from last year.
  • Latest data reveals that DiaMedica Therapeutics reported EBITDA Margin of 277.4% as of Q3 2018.
  • DiaMedica Therapeutics' EBITDA Margin's 5-year high stood at 277.4% during Q3 2018, with a 5-year trough of 277.4% in Q3 2018.